Peng Qiu, associate professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory, has been named an ISAC Marylou Ingram Scholar by the International Society for Advancement of Cytometry (ISAC). Qiu’s scholar status extends through the year 2022. Scholars specialize in state of the art knowledge related to biomedicine, technology, and other areas of emerging sciences relevant to cytometry. The program is designed as a career development initiative for those under the age of 40.
Cytometry is the measurement of the characteristics of cells. One use of cytometry is in cell biology research and in medical diagnostics to characterize cells in a wide range of applications associated with diseases such as cancer.
Qiu’s research interests lie in the area of bioinformatics and computational biology. One of his main focuses is computational algorithms for analyzing single-cell characterizations, measured by flow cytometry, CyTOF, single-cell RNAseq, image-based profiling, microfluidics, and other single-cell technologies. ISAC is a great community and valuable resource for him to advance his research and develop collaborations.
CONTACT:
Walter Rich
Wallace H. Coulter Department of Biomedical Engineering
Georgia Institute of Technology
Media Contact
Walter Rich
Keywords
Latest BME News
Researchers demonstrate stem cell treatment without chemotherapy and painful bone marrow procedure
BME researchers explore the critical role of mechanical force in rare genetic disorder
Researchers develop spatial transcriptomics toolkit that provides new insights into the molecular processes of life
Air Detectives take top prize to give department three straight victories in Expo competition
Coulter BME community gathers at the Fabulous Fox to celebrate anniversary of unique public-private partnership
Coskun pioneering new research area and building a company around iseqPLA technology
BME undergraduate student and competitive skater Sierra Venetta has found success on and off the ice
BME researcher Ankur Singh using new technology to uncover weakened response in cancer patients